Gilead assumed with an Overweight at Piper Jaffray. Piper Jaffray analyst Tyler Van Buren assumed coverage of Gilead Sciences (GILD) with an Overweight rating and $85 price target. The analyst, after speaking with management, has a “high level of conviction” that pricing for the hepatitis C virus franchise has finally stabilized. It is inconceivable that AbbVie (ABBV) will continue to be irrational on pricing, Van Buren tells investors in a research note.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.